We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

231 hedge funds and large institutions have $1.72B invested in PDL BioPharma, Inc. in 2014 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 78 increasing their positions, 71 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 29

22% more capital invested

Capital invested by funds: $1.41B → $1.72B (+$311M)

4% more funds holding

Funds holding: 222 → 231 (+9)

10% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 71

34% less call options, than puts

Call options by funds: $3.82M | Put options by funds: $5.79M

Holders
231
Holders Change
+9
Holders Change %
+4.05%
% of All Funds
6.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
40
Increased
78
Reduced
71
Closed
29
Calls
$3.82M
Puts
$5.79M
Net Calls
-$1.97M
Net Calls Change
-$4.08M

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$21.5M
2
QI
QS Investors
New York
+$13.7M
3
HA
Hays Advisory
Tennessee
+$12.1M
4
Morgan Stanley
Morgan Stanley
New York
+$10.8M
5
Renaissance Technologies
Renaissance Technologies
New York
+$7.88M

Top Sellers

Rank Fund Capital Flow
1
Norges Bank
Norges Bank
Norway
-$15.9M
2
AQR Capital Management
AQR Capital Management
Connecticut
-$11.3M
3
GAM
Gotham Asset Management
New York
-$7.09M
4
Invesco
Invesco
Georgia
-$5.22M
5
CIM
Calvert Investment Management
Maryland
-$4.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
NSIM
201
North Star Investment Management
Illinois
$22K – – –
RIA
202
Regal Investment Advisors
Michigan
$22K +$22.4K +2,409 +478%
First Eagle Investment Management
203
First Eagle Investment Management
New York
$21K – – –
PIA
204
Peachtree Investment Advisors
Georgia
$18K +$22.3K +2,400 New
BRWM
205
B. Riley Wealth Management
Tennessee
$17K +$798 +86 +4%
OIA
206
Optimum Investment Advisors
Illinois
$16K – – –
SFSIG
207
San Francisco Sentry Investment Group
California
$15K – – –
TSW
208
Thompson Siegel & Walmsley
Virginia
$15K – – –
JG
209
Jefferies Group
New York
$13K +$15.7K +1,686 New
EWM
210
Evercore Wealth Management
New York
$8K – – –
CFA
211
Carroll Financial Associates
North Carolina
$5K – – –
PR
212
Payden & Rygel
California
$5K – – –
FANJ
213
Financial Architects (New Jersey)
New Jersey
$4K – – –
LWCFA
214
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$4K – – –
MWP
215
MYCIO Wealth Partners
Pennsylvania
$4K – – –
PIM
216
Parasol Investment Management
Illinois
$4K – – –
Envestnet Asset Management
217
Envestnet Asset Management
Illinois
$3K -$8.78K -946 -68%
WA
218
Winfield Associates
Ohio
$2K -$1.86K -200 -40%
BPBT
219
Boston Private Bank & Trust
Massachusetts
$2K – – –
WCBA
220
Weaver C. Barksdale & Associates
Tennessee
$2K +$3.06K +330 New
FCCM
221
First City Capital Management
Georgia
$1.79K – – –
PIA
222
Piedmont Investment Advisors
North Carolina
$1.43K – – –
ClearBridge Investments
223
ClearBridge Investments
New York
$1K – – –
WTC
224
WhitTier Trust Company
Nevada
$1K – – –
FHA
225
First Horizon Advisors
Tennessee
$1K +$1.66K +179 New
7 8
9
10 11

PDLI Hedge Fund Activity: Q3 2014 in Review

231 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2014, worth a combined $1.72B — up 22% from $1.41B a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new PDLI positions and 29 closed out — a net gain of 11 holders — while 78 added to existing stakes and 71 trimmed.

The largest buyer was Bank of America, adding an estimated $21.5M. The largest seller was Norges Bank, cutting an estimated $15.9M.

  • 231 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2014, up from 222 in Q2 2014.
  • Funds reported $1.72B of PDL BioPharma, Inc. stock for Q3 2014, up 22% quarter-over-quarter.
  • 40 funds opened new PDL BioPharma, Inc. positions in Q3 2014 and 29 closed out, a net change of +11 holders.
  • The largest PDL BioPharma, Inc. buyer in Q3 2014 was Bank of America, an estimated $21.5M added.
  • The largest PDL BioPharma, Inc. seller in Q3 2014 was Norges Bank, an estimated $15.9M sold.

Based on aggregated 13F filings for Q3 2014.